ProQR Therapeutics N.V. (PRQR) Key Metrics
PRQR key metrics, 2016–2025
Fiscal year ended December 31, 2025 · eurosPRQR returns How much profit the business earns on the capital it uses.
PRQR financial health Debt, liquidity and how easily interest is covered.
PRQR efficiency & capital use Working capital cycle and where the cash goes.
PRQR returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PRQR debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PRQR key metrics in euros
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −54.1% | −40.4% | −47.9% | −64.1% | −61.0% | −53.0% | −57.2% | −52.7% | −84.5% | −50.9% |
| Return on invested capital (ROIC) | — | — | — | — | — | −463.5% | — | −426.4% | — | — |
| Return on assets (ROA) | −26.5% | −17.0% | −16.8% | −30.6% | −33.8% | −36.8% | −46.9% | −42.4% | −65.7% | −44.0% |
| Return on tangible assets | −30.6% | −16.0% | −18.5% | −35.2% | −25.5% | −38.5% | −43.0% | −33.5% | −68.5% | −56.6% |
| Free cash flow margin | −352.2% | −200.0% | 309.7% | — | — | — | — | −627.3% | — | — |
| Financial health | ||||||||||
| Total debt | €16.4M | €16.1M | €21.8M | €23.4M | €68.7M | €41.9M | €15.2M | €28.1M | €8.7M | €4.8M |
| Cash & short-term investments | €108.5M | €154.7M | €131.4M | €101.1M | €213.3M | €92.8M | €125.7M | €105.6M | €57.8M | €62.4M |
| Net debt | −€92.1M | −€138.6M | −€109.6M | −€77.7M | −€144.6M | −€50.9M | −€110.4M | −€77.4M | −€49.1M | −€57.6M |
| Debt / equity | 0.28 | 0.18 | 0.48 | 0.33 | 0.53 | 0.60 | 0.14 | 0.30 | 0.18 | 0.09 |
| Debt / assets | 0.12 | 0.09 | 0.14 | 0.13 | 0.29 | 0.35 | 0.12 | 0.26 | 0.14 | 0.07 |
| Net debt / EBITDA | — | — | — | — | — | — | — | — | −46.06 | — |
| Current ratio | 3.09 | 3.95 | 3.54 | 7.36 | 6.94 | 7.77 | 10.43 | 13.28 | 5.95 | 9.24 |
| Quick ratio | 3.09 | 3.95 | 3.54 | 7.36 | 6.93 | 7.74 | 10.40 | 13.17 | 5.95 | 9.08 |
| Interest coverage | -48.7 | -28.3 | -26.5 | -12.7 | -16.8 | -20.8 | -53.0 | -44.8 | -67.9 | -73.6 |
| Working capital | €79.5M | €119.0M | €95.9M | €142.4M | €186.4M | €85.3M | €116.4M | €100.2M | €50.5M | €58.3M |
| Invested capital | −€34.1M | −€46.9M | −€63.8M | −€6.1M | −€15.1M | €19.0M | −€4.6M | €15.2M | −€1.8M | −€1.5M |
| Tangible asset value | €58.0M | €91.7M | €45.7M | €71.2M | €128.8M | €69.2M | €105.3M | €92.7M | €47.2M | €56.0M |
| Net current asset value | €43.2M | €77.1M | €27.1M | €53.2M | €108.2M | €46.3M | €102.1M | €90.8M | €44.2M | €52.3M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | €0 | €0 | €0 | €0 |
| Share buybacks (net) | — | — | — | — | — | — | €0 | €0 | €0 | €0 |
| Capex / revenue | 6.7% | 7.5% | 21.0% | 19.7% | 36.3% | 89.8% | 30.0% | 6.3% | — | 111.3% |
| Capex / operating cash flow | — | — | 6.4% | — | — | — | — | — | — | — |
| Capex / depreciation | 0.38 | 0.51 | 0.55 | 0.28 | 0.21 | 0.39 | 0.28 | 0.31 | 0.11 | 2.04 |
| Stock-based compensation / revenue | 26.3% | 13.5% | 47.7% | 79.8% | 465.6% | 761.7% | 471.2% | 65.2% | — | 107.5% |
| R&D / revenue | 266.5% | 192.3% | 386.1% | 1,415.3% | 3,162.5% | 3,706.0% | 2,405.1% | 597.3% | — | 1,398.9% |
| SG&A / revenue | 98.6% | 72.3% | 249.2% | 518.9% | 1,301.0% | 1,329.9% | 666.7% | 253.8% | — | 415.3% |
| Efficiency | ||||||||||
| Days sales outstanding | 96.4 | 33.8 | 1,750.6 | 3,149.4 | 261.8 | 410.5 | 243.5 | 66.7 | — | 262.6 |
| Days of inventory on hand | — | — | 9.4 | 20.1 | — | 59.8 | 1.9 | 180.4 | 226.5 | 244.5 |
| Days payables outstanding | 25.8 | — | 2,898.5 | 46.9 | — | 64.0 | 1.0 | 146.7 | 182.6 | 186.2 |
| Cash conversion cycle (days) | 70.7 | — | -1,138.4 | 3,122.7 | — | 406.3 | 244.4 | 100.4 | — | 320.9 |
| Receivables turnover | 3.79 | 10.80 | 0.21 | 0.12 | 1.39 | 0.89 | 1.50 | 5.47 | 0.00 | 1.39 |
| Payables turnover | 14.17 | 0.00 | 0.13 | 7.79 | 0.00 | 5.70 | 368.23 | 2.49 | 2.00 | 1.96 |
| Inventory turnover | — | — | 38.89 | 18.11 | 0.00 | 6.10 | 188.58 | 2.02 | 1.61 | 1.49 |
| Asset turnover | 0.10 | 0.12 | 0.04 | 0.02 | 0.01 | 0.01 | 0.02 | 0.06 | 0.00 | 0.03 |
| Average receivables | €4.0M | €1.7M | €31.2M | €31.0M | €957,378 | €1.2M | €1.3M | €903,088 | €1.1M | €1.6M |
| Average payables | €183,277 | €859,416 | €1.1M | €317,784 | €243,804 | €384,958 | €317,256 | €395,318 | €500,797 | €653,666 |
| Average inventory | — | — | €3,433 | €136,660 | €322,728 | €359,500 | €619,500 | €486,000 | €621,500 | €858,500 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
Computed from PRQR's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in euros; data from EODHD. Averages use the opening and closing balance of each year.
PRQR valuation and financial ratios
ProQR Therapeutics earned a return on equity of −54.1% in fiscal 2025. It ended the year with €16.4 million of debt and €108.5 million in cash and short-term investments, a net cash position of €92.1 million.
See the PRQR income statement, the PRQR chart for price history, or the PRQR stock overview for the latest quote and news.
PRQR key metrics FAQ
What is ProQR Therapeutics's return on equity?
ProQR Therapeutics's return on equity (ROE) was −54.1% in fiscal 2025: net income of -€40.5 million on average shareholders' equity of €74.8 million.
How much debt does ProQR Therapeutics have?
ProQR Therapeutics had total debt of €16.4 million at the end of fiscal 2025, a debt-to-equity ratio of 0.28 and more cash than debt.
What is ProQR Therapeutics's current ratio?
ProQR Therapeutics's current ratio was 3.09 at the end of fiscal 2025: current assets were 3.09 times current liabilities.